2025
Acute Systemic Sclerosis-Associated Cardiomyopathy That Improved With Glucocorticoids and Cyclophosphamide
Gustafson A, Trinh K, Lomasney J, Shah S, Hinchcliff M. Acute Systemic Sclerosis-Associated Cardiomyopathy That Improved With Glucocorticoids and Cyclophosphamide. JACC Case Reports 2025, 30: 102948. PMID: 39972702, PMCID: PMC11862153, DOI: 10.1016/j.jaccas.2024.102948.Peer-Reviewed Original ResearchSystemic sclerosisEndomyocardial biopsyDiffuse cutaneous systemic sclerosisCutaneous systemic sclerosisAssociated with increased mortalityT lymphocyte infiltrationAcute heart failureIntravenous cyclophosphamideDiagnosing myocarditisDiastolic dysfunctionSystolic dysfunctionT lymphocytesHeart failureProlonged recoveryPatientsCardiomyopathy treatmentCyclophosphamideBiopsyCardiomyopathyGlucocorticoidDysfunctionMyopericarditisMyocarditisCould metabolic imaging and artificial intelligence provide a novel path to non-invasive aneuploidy assessments? A certain clinical need
Horta F, Sakkas D, Ledger W, Goldys E, Gilchrist R. Could metabolic imaging and artificial intelligence provide a novel path to non-invasive aneuploidy assessments? A certain clinical need. Reproduction Fertility And Development 2025, 37 PMID: 39874158, DOI: 10.1071/rd24122.Peer-Reviewed Original ResearchConceptsPGT-AMetabolic imagingAneuploid embryosEmbryo biopsyEmbryo selectionNon-invasive PGT-APre-implantation genetic testingEnhancing embryo selectionNon-invasive metabolic imagingAneuploidy assessmentEmbryo ploidyGenetic testingInvasive natureClinical practicePotential mosaicismClinical needBiopsyFluorescence lifetime imaging microscopyTreatment costsAneuploidyActivation signatureMeasuring cellular metabolismHuman fibroblastsNon-invasive technologyDiagnostic practiceThe evolving role of liver biopsy: Current applications and future prospects
Gopal P, Hu X, Robert M, Zhang X. The evolving role of liver biopsy: Current applications and future prospects. Hepatology Communications 2025, 9: e0628. PMID: 39774070, PMCID: PMC11717517, DOI: 10.1097/hc9.0000000000000628.Peer-Reviewed Original ResearchNon-uremic calciphylaxis: A dermatologic complication in both MASH and alcohol-associated cirrhosis
Balter D, Cao Y, Garritano J, Micevic G, Sanchez A. Non-uremic calciphylaxis: A dermatologic complication in both MASH and alcohol-associated cirrhosis. Clinical Nephrology - Case Studies 2025, 13: 8-12. PMID: 39949516, PMCID: PMC11823000, DOI: 10.5414/cncs111578.Peer-Reviewed Original ResearchNon-uremic calciphylaxisDermatological complicationsAlcohol-associated cirrhosisPainful skin lesionsAcute kidney injurySodium thiosulfate therapyInfectious complicationsKidney injuryTreatment optionsSkin biopsiesHepatic encephalopathyWork-upSkin lesionsCalciphylaxisCirrhosisComplicationsThiosulfate therapyAlcohol associationsPatientsTreatmentBiopsyPrognosisTherapyLesionsEncephalopathyNeural network analysis as a novel skin outcome in a trial of belumosudil in patients with systemic sclerosis
Gunes I, Bernstein E, Cowper S, Panse G, Pradhan N, Camacho L, Page N, Bundschuh E, Williams A, Carns M, Aren K, Fantus S, Volkmann E, Bukiri H, Correia C, Kolachalama V, Wilson F, Mawe S, Mahoney J, Hinchcliff M. Neural network analysis as a novel skin outcome in a trial of belumosudil in patients with systemic sclerosis. Arthritis Research & Therapy 2025, 27: 85. PMID: 40217251, DOI: 10.1186/s13075-025-03508-9.Peer-Reviewed Original ResearchConceptsModified Rodnan skin scoreSystemic sclerosisFibrosis scoreHistological parametersDiffuse cutaneous systemic sclerosisInterquartile rangeSystemic sclerosis skin biopsiesRodnan skin scoreCutaneous systemic sclerosisOpen-label trialSkin scorePathological parametersSkin biopsiesBiopsySkin outcomesStudy terminationFibrosisHistological analysisBlinded dermatopathologistStained sectionsSpearman correlationBelumosudilPatientsSkin featuresScores
2024
External Validation of an Electronic Health Record-Based Diagnostic Model for Histological Acute Tubulointerstitial Nephritis.
Moledina D, Shelton K, Menez S, Aklilu A, Yamamoto Y, Kadhim B, Shaw M, Kent C, Makhijani A, Hu D, Simonov M, O'Connor K, Bitzel J, Thiessen-Philbrook H, Wilson F, Parikh C. External Validation of an Electronic Health Record-Based Diagnostic Model for Histological Acute Tubulointerstitial Nephritis. Journal Of The American Society Of Nephrology 2024 PMID: 39500309, DOI: 10.1681/asn.0000000556.Peer-Reviewed Original ResearchJohns Hopkins HospitalAcute tubulointerstitial nephritisValidation cohortKidney biopsyTubulointerstitial nephritisDiagnosis of acute tubulointerstitial nephritisProportion of biopsiesElectronic health recordsAnalyzed patientsDevelopment cohortBaseline prevalenceAccurate diagnosisBiopsyCohortHealth recordsClinician's abilityDiagnostic modelPotential predictorsNephritisAssess discriminationKidneyAUCA multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features
Klughammer J, Abravanel D, Segerstolpe Å, Blosser T, Goltsev Y, Cui Y, Goodwin D, Sinha A, Ashenberg O, Slyper M, Vigneau S, Jané‐Valbuena J, Alon S, Caraccio C, Chen J, Cohen O, Cullen N, DelloStritto L, Dionne D, Files J, Frangieh A, Helvie K, Hughes M, Inga S, Kanodia A, Lako A, MacKichan C, Mages S, Moriel N, Murray E, Napolitano S, Nguyen K, Nitzan M, Ortiz R, Patel M, Pfaff K, Porter C, Rotem A, Strauss S, Strasser R, Thorner A, Turner M, Wakiro I, Waldman J, Wu J, Gómez Tejeda Zañudo J, Zhang D, Lin N, Tolaney S, Winer E, Boyden E, Chen F, Nolan G, Rodig S, Zhuang X, Rozenblatt-Rosen O, Johnson B, Regev A, Wagle N. A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features. Nature Medicine 2024, 30: 3236-3249. PMID: 39478111, PMCID: PMC11564109, DOI: 10.1038/s41591-024-03215-z.Peer-Reviewed Original ResearchClinicopathological featuresLocal T cell infiltrationT cell infiltrationMetastatic breast cancerBreast cancer biopsiesCancer-related deathsEpithelial-to-mesenchymal transitionMetastatic diseaseClinically relevant discoveriesTumor biopsiesTumor microenvironmentCancer biopsiesBreast cancerAnatomical sitesMacrophage populationsSingle-nucleus RNA sequencingBiopsyH&E stainingConsecutive serial sectionsClinical annotationTumorSingle-cellSpatial expression characteristicsSerial sectionsCell type compositionDiscordances Between Radiology and Pathology
Harigopal M, Verma A, Andrejeva L, Lewin J. Discordances Between Radiology and Pathology. 2024, 375-391. DOI: 10.1007/978-3-031-65711-5_14.Peer-Reviewed Original ResearchPathological findingsImaging characteristicsMRI-guided biopsyFalse-negative diagnosesRadiology-pathology correlationH&E levelsPreoperative biopsyStereotactic biopsySurgical excisionPercutaneous biopsyDiscordant casesSonographic guidanceBreast biopsyAncillary stainsHistopathological findingsBiopsyMammographic lesionsLesionsIndividual pathologistsPathologistsPotential causesUltrasoundWeekly conferencesImage featuresDiscordanceMRI Breast Findings
Narasimhamurthy M, O’Brien S, Andrejeva L, Nayak A. MRI Breast Findings. 2024, 235-267. DOI: 10.1007/978-3-031-65711-5_9.Peer-Reviewed Original ResearchMagnetic resonance imagingNon-mass enhancementBreast lesionsBreast magnetic resonance imagingPracticing pathologistsMagnetic resonance imaging findingsRadiologic-pathologic correlationBreast core biopsiesMalignant breast lesionsDiagnosing breast lesionsCore biopsyMRI findingsBreast biopsyImaging examinationsFalse-positive rateBiopsyResonance imagingLesionsBreastImaging techniquesPathologistsImage patternsImplementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective
Breadner D, Hwang D, Husereau D, Cheema P, Doucette S, Ellis P, Kassam S, Leighl N, Maziak D, Selvarajah S, Sheffield B, Juergens R. Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective. Current Oncology 2024, 31: 6017-6031. PMID: 39451753, PMCID: PMC11505603, DOI: 10.3390/curroncol31100449.Peer-Reviewed Original ResearchNon-small-cell lung cancerAdvanced non-small-cell lung cancerCirculating tumor DNALung cancerMolecular profilingLiquid biopsyImplementation of liquid biopsiesComprehensive molecular profilingNon-small-cellHigh-risk patientsCancer-related deathsMinimally invasive methodTissue biopsy samplesTumor DNAInsufficient tissueMultidisciplinary working groupTherapy selectionTissue biopsiesBiomarker testingBiopsy samplesBiopsyGold standardInvasive methodEligibility criteriaCancerEvaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group
Sargen M, Barnhill R, Elder D, Swetter S, Prieto V, Ko J, Bahrami A, Gerami P, Karunamurthy A, Pappo A, Schuchter L, LeBoit P, Yeh I, Kirkwood J, Jen M, Dunkel I, Durham M, Christison-Lagay E, Austin M, Aldrink J, Mehrhoff C, Hawryluk E, Chu E, Busam K, Sondak V, Messina J, Puig S, Colebatch A, Coughlin C, Berrebi K, Laetsch T, Mitchell S, Seynnaeve B. Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. Journal Of Clinical Oncology 2024, 43: 1157-1167. PMID: 39365959, PMCID: PMC11908957, DOI: 10.1200/jco.24.01154.Peer-Reviewed Original ResearchSentinel lymph node biopsyAtypical Spitz tumorsCutaneous melanomaSpitz tumorsRe-excisionSurgical managementMelanocytic tumorsSurgical management of cutaneous melanomaManagement of cutaneous melanomaNational Comprehensive Cancer Network guidelinesLymph node biopsyDefinitive surgical treatmentProgression to CMChildren's Oncology GroupDiagnosis of CMNode biopsyExcisional biopsyOncology GroupMalignant potentialSurgical treatmentNetwork guidelinesBiopsyClinicopathological evaluationCohort studyMelanocytic neoplasmsA brave new framework for glioma drug development
Hotchkiss K, Karschnia P, Schreck K, Geurts M, Cloughesy T, Huse J, Duke E, Lathia J, Ashley D, Nduom E, Long G, Singh K, Chalmers A, Ahluwalia M, Heimberger A, Bagley S, Todo T, Verhaak R, Kelly P, Hervey-Jumper S, de Groot J, Patel A, Fecci P, Parney I, Wykes V, Watts C, Burns T, Sanai N, Preusser M, Tonn J, Drummond K, Platten M, Das S, Tanner K, Vogelbaum M, Weller M, Whittle J, Berger M, Khasraw M. A brave new framework for glioma drug development. The Lancet Oncology 2024, 25: e512-e519. PMID: 39362262, DOI: 10.1016/s1470-2045(24)00190-6.Peer-Reviewed Original ResearchConceptsBrain tumorsBenefits of biopsyBrain tumor therapyLiquid biopsy technologiesTissue samplesPostoperative deficitsBiopsy techniqueBiopsy technologyEffective therapySurgical trialsClinical trialsTumor therapyResistance mechanismsTumorTherapyPatientsDrug developmentTissue analysisBrainTrialsTissueBiopsyGliomaRegulatory agenciesADVANCED SPERM AGE ≥50 YEAR IS ASSOCIATED WITH AN INCREASE IN SEGMENTAL ANEUPLOIDY RATES: A MULTI-SITE DONOR OOCYTE POPULATION STUDY OF 2124 BIOPSIED EMBRYOS WITH PGTSEQ
Barrett F, Kadesh A, Zhan Y, Gill P, Vessa B, Whitehead C, Puchalt N, Mounts E, Seli E, Werner M, Jalas C, Franasiak J. ADVANCED SPERM AGE ≥50 YEAR IS ASSOCIATED WITH AN INCREASE IN SEGMENTAL ANEUPLOIDY RATES: A MULTI-SITE DONOR OOCYTE POPULATION STUDY OF 2124 BIOPSIED EMBRYOS WITH PGTSEQ. Fertility And Sterility 2024, 122: e35. DOI: 10.1016/j.fertnstert.2024.07.164.Peer-Reviewed Original ResearchHigher sensitivity of pericardial fluid cytology than biopsy in malignant effusions with potential explanation of false‐negative cytology: A multi‐institutional analysis
Takeda K, Gereg C, Liu X, Ma W, Bearse M, Tang H, Delfino I, Huang E, Lin X, Chandler J, Wang H. Higher sensitivity of pericardial fluid cytology than biopsy in malignant effusions with potential explanation of false‐negative cytology: A multi‐institutional analysis. Cytopathology 2024, 36: 31-40. PMID: 39301772, DOI: 10.1111/cyt.13447.Peer-Reviewed Original ResearchPericardial fluid cytologySensitivity of cytologyMalignant pericardial effusionMulti-institutional analysisFluid cytologyCytology casesPericardial effusionDiagnostic sensitivity of cytologyFalse-negative cytologyFalse-negative resultsSite of originConcurrent biopsyPericardial biopsyHistological subtypesMalignant effusionsHistologic reviewPericardial involvementRetrospective reviewMalignant casesPoor prognosisImmunohistochemistry studiesClinical historyDiagnostic superiorityBiopsyCytologyConventional and Contrast-enhanced US of the Lung: From Performance to Diagnosis.
Jiménez-Serrano S, Páez-Carpio A, Doménech-Ximenos B, Cornellas L, Sánchez M, Revzin M, Vollmer I. Conventional and Contrast-enhanced US of the Lung: From Performance to Diagnosis. RadioGraphics 2024, 44: e230171. PMID: 38935548, DOI: 10.1148/rg.230171.Peer-Reviewed Original ResearchConceptsPeripheral lung diseaseContrast-enhanced USDiagnosis of peripheral lung diseasePercutaneous biopsyLung USEnhancement patternLung diseaseImage-guided percutaneous biopsyAccurate differential diagnosisDiagnostic chest imagingLung biopsySubpleural lesionsConventional USDifferential diagnosisPathological findingsPulmonary physiologyChest imagingArterial supplyBiopsyLungDiagnostic testsDiagnosisSoft tissueDiseaseImaging timeTranslation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology
Tan W, Nagabhyrava S, Ang-Olson O, Das P, Ladel L, Sailo B, He L, Sharma A, Ahuja N. Translation of Epigenetics in Cell-Free DNA Liquid Biopsy Technology and Precision Oncology. Current Issues In Molecular Biology 2024, 46: 6533-6565. PMID: 39057032, PMCID: PMC11276574, DOI: 10.3390/cimb46070390.Peer-Reviewed Original ResearchCell-free DNA liquid biopsyCell-free DNALiquid biopsy technologiesLiquid biopsyBiopsy technologyEarly cancer detectionClinical applicationCfDNA-based liquid biopsyMonitoring residual diseaseEarly detection testsCancer detectionPotential of epigeneticsPersonalized cancer treatmentImprove cancer outcomesTissue of originFragmentation pattern analysisResidual diseaseDNA methylationMulti-cancer early detection testTreatment responseBiopsyCancer outcomesCancer preventionEpigeneticsPrecision oncologyRisk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy
Diaz G, Webb L, Rabil M, Lokeshwar S, Choksi A, Leapman M, Sprenkle P. Risk Factors and Contemporary Management Options for Pain and Discomfort Experienced During a Prostate Biopsy. Current Urology Reports 2024, 25: 243-252. PMID: 38896314, DOI: 10.1007/s11934-024-01220-w.Peer-Reviewed Original ResearchProstate biopsyRisk factorsEffective pain management strategiesDiagnosed prostate cancerPain management strategiesIn-office proceduresModern management optionsNonadherence to treatmentContemporary management optionsEnhance patient comfortInnovative imaging modalitiesExperience of painFusion biopsyProstate volumePain intensityProstate cancerPain varyPatient ageIncreased painFollow-upIn-officeManagement optionsSurveillance adherenceBiopsyPharmacological analgesicsEBUS-TBNA pleural biopsy reveals prostate cancer metastasis: A rare case report and review of the literature
Sampsonas F, Komninos D, Sotiropoulou V, Katsaras M, Gkanetsou D, Papaioannou O, Tsiri P, Tzelepi V, Tzouvelekis A. EBUS-TBNA pleural biopsy reveals prostate cancer metastasis: A rare case report and review of the literature. Pneumon 2024, 37: 1-4. DOI: 10.18332/pne/188870.Peer-Reviewed Original ResearchOncogenic composite mutations can be predicted by co‐mutations and their chromosomal location
Küçükosmanoglu A, van der Borden C, de Boer L, Verhaak R, Noske D, Wurdinger T, Radonic T, Westerman B. Oncogenic composite mutations can be predicted by co‐mutations and their chromosomal location. Molecular Oncology 2024, 18: 2407-2422. PMID: 38757376, PMCID: PMC11459034, DOI: 10.1002/1878-0261.13636.Peer-Reviewed Original ResearchComposite mutationCo-mutationsMutation-specific drugsCell line dataChromosomal locationSub-clonal populationsGenetic heterogeneitySub-clonesTherapy resistanceSelection pressureGenetic eventsStratify patientsKRAS geneResistance-causing mutationsCancer patientsBiopsy samplesMutationsPatientsGenesPrecision medicineTherapyRiskChromosomeBiopsyBRAFSurveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry
Khush K, Hall S, Kao A, Raval N, Dhingra R, Shah P, Bellumkonda L, Ravichandran A, Van Bakel A, Uriel N, Patel S, Pinney S, DePasquale E, Baran D, Pinney K, Oreschak K, Kobulnik J, Shen L, Teuteberg J. Surveillance with dual noninvasive testing for acute cellular rejection after heart transplantation: Outcomes from the Surveillance HeartCare Outcomes Registry. The Journal Of Heart And Lung Transplantation 2024, 43: 1409-1421. PMID: 38759766, DOI: 10.1016/j.healun.2024.05.003.Peer-Reviewed Original ResearchAcute cellular rejectionIncidence of acute cellular rejectionBiopsy rateGene expression profilesNon-invasive testsMolecular testingDd-cfDNACellular rejectionGraft dysfunctionHeart transplantationFollow-up testing ratesIncidence of graft dysfunctionLow biopsy rateFollow-up biopsiesPositive likelihood ratioNon-invasive surveillanceBiopsy dataClinical decision-makingExcellent survivalOutcomes RegistryFollow-upLow incidenceBiopsyPositive groupDual testing
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply